Here are 1-3 brief analogies for PMV Pharmaceuticals (PMVP):

• Vertex Pharmaceuticals for cancer's p53 mutations.
• A highly specialized Genentech, solely focused on correcting p53 mutations in cancer.

• PC14586: A lead small molecule drug candidate designed to correct the p53 Y220C mutation and restore wild-type p53 function.
• Wild-type p53 Induced-Phosphatase (WIP1) Program: A drug development program targeting the Wild-type p53 Induced-Phosphatase pathway in the context of mutant p53.
• R282W Program: A drug development program specifically targeting the p53 R282W mutation.
• R273H Program: A drug development program specifically targeting the p53 R273H mutation.
• Other p53 Hotspot Mutations Programs: Drug development programs aimed at addressing additional common p53 hotspot mutations in cancer.

David H. Mack, Ph.D. Co-Founder, President & CEO

David H. Mack co-founded PMV Pharmaceuticals in 2013. Prior to PMV Pharma, he was a general partner at Alta Partners, a venture capital firm, from 2002 to 2013. His first investment at Alta was Angiosyn, where he served as a director and CEO; Angiosyn was later acquired by Pfizer in 2005. Before joining Alta, Dr. Mack co-founded and was Vice President of Genomics Research at Eos Biotechnology, which was acquired by Protein Design Labs in 2003. He also served as Head of Cancer Biology at Affymetrix from 1994 to 1997. Dr. Mack was a pivotal member of the Polymerase Chain Reaction (PCR) Invention Group at Cetus in the mid-1980s. He has served on the Board of Directors for numerous biotechnology companies, including Aerie Pharmaceuticals, Aduro Biotech, and Sutro Biopharma.

Michael Carulli Chief Financial Officer

Michael Carulli was promoted to Chief Financial Officer in January 2024, succeeding Winston Kung. He joined PMV Pharmaceuticals in 2020 as Vice President, Finance, and played a crucial role in the company's initial public offering process. Mr. Carulli later took over all finance and accounting functions and was promoted to Senior Vice President, Finance in March 2023.

Deepika Jalota, Pharm.D. Chief Development Officer

Deepika Jalota joined PMV Pharmaceuticals in 2019 and was promoted to Chief Development Officer in May 2023. She possesses a proven track record of successful clinical development and drug approvals in oncology, including tumor-agnostic drugs like larotrectinib.

Robert Ticktin General Counsel and Chief Operating Officer

Robert Ticktin serves as the General Counsel and Chief Operating Officer for PMV Pharmaceuticals. In January 2024, his responsibilities were expanded to include the management of Operations, Human Resources, IT, and Facilities.

Marc Fellous, M.D. Senior Vice President, Head of Clinical Development and Medical Affairs

Marc Fellous joined PMV Pharma in April 2022 as Vice President, Clinical Development and Medical Affairs, and was promoted to Senior Vice President, Head of Clinical Development and Medical Affairs in May 2023. Prior to joining PMV Pharma, he was the Global Medical Affairs Head for the larotrectinib and selitrectinib programs at Bayer. Dr. Fellous has over 13 years of experience in leadership roles at Bayer and Roche, where he contributed to the strategy and launch of multiple successful oncology products.

The key risks to PMV Pharmaceuticals (PMVP) primarily revolve around the inherent challenges of drug development in the biotechnology sector, particularly for a company in the clinical stage with a lead product candidate.

1. Clinical Trial and Regulatory Approval Risk: The most significant risk for PMV Pharmaceuticals is the successful outcome of its ongoing clinical trials, particularly for its lead product candidate, rezatapopt (PC14586), which targets the p53 Y220C mutation. The company's future and valuation are heavily dependent on rezatapopt meeting efficacy and safety endpoints in trials like the Phase 2 PYNNACLE study, and subsequently securing regulatory approvals. A failure in clinical trials or an inability to obtain necessary regulatory clearances would severely impact the company's prospects.
2. Cash Runway and Future Funding Risk: As a pre-revenue biotechnology company focused on research and development, PMV Pharmaceuticals is burning cash at a significant rate. While the company reported a cash, cash equivalents, and marketable securities balance of $112.9 million as of December 31, 2025, which is projected to fund operations only through the end of the second quarter of 2027, this implies a need for future financing. Sustaining ongoing losses and funding extensive clinical development activities without product revenue presents a continuous financial risk, necessitating further capital raises.
3. Single-Asset Focus Risk: PMV Pharmaceuticals' strategic risk is substantially concentrated on the success of rezatapopt (PC14586). The company's "single-asset focus" means that if the PYNNACLE trial results for this lead candidate significantly differ from promising preliminary data, the company's stock thesis could collapse. While PMV Pharmaceuticals has other mutant p53 programs, the current emphasis and valuation appear heavily tied to rezatapopt's development.

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) focuses on therapies for p53 mutations in cancer, with its lead product candidate, rezatapopt (PC14586), designed to correct the p53 Y220C mutation.

The addressable market for PMV Pharmaceuticals' main product, rezatapopt (PC14586), targeting TP53 Y220C mutations, has been estimated as follows:

• For second-line and later ovarian cancer patients with TP53 Y220C mutations, the estimated market opportunity in the U.S. is between $350 million and $420 million. Globally, this market segment is estimated to be up to $630 million.
• Analysts have estimated peak sales for PMV Pharmaceuticals' lead asset (rezatapopt) to be between $400 million and $600 million.
• More broadly, rezatapopt, with its tumor-agnostic approach, is considered to have the potential to address a $3.2 billion oncology market across multiple solid tumors.

The overall global market for Mutant p53 Reactivator and p53 Restoration Therapeutics, which encompasses the therapeutic area PMV Pharmaceuticals operates in, was valued at approximately $1.9 billion in 2025 and is projected to reach nearly $3.4 billion by 2030. By 2035, this global market is expected to exceed $5.8 billion.

PMV Pharmaceuticals (PMVP) is a precision oncology company currently in a developmental stage with no product sales revenue. The expected drivers of future revenue growth over the next 2-3 years are directly tied to the advancement and commercialization of its lead product candidate, rezatapopt (also known as PC14586), a small molecule that corrects the p53 Y220C mutation in cancer.

1. Successful Regulatory Approval and Commercial Launch of Rezatapopt in Ovarian Cancer: The primary driver of future revenue for PMV Pharmaceuticals hinges on the successful New Drug Application (NDA) submission and subsequent regulatory approval of rezatapopt for platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation. The company anticipates submitting an NDA in the first quarter of 2027, positioning it for potential market entry within the next 2-3 years.
2. Market Exclusivity from Orphan Drug Designation: Rezatapopt received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in March 2026 for the treatment of TP53 Y220C positive ovarian cancer. This designation provides significant benefits, including seven years of market exclusivity in the U.S. if the treatment is approved, which will protect its initial revenue stream from direct competition.
3. Efficacy and Adoption Based on Positive Clinical Data: The strong interim Phase 2 results from the PYNNACLE trial, which demonstrated a 46% overall response rate (ORR) in the ovarian cancer cohort, are crucial for driving physician and patient adoption upon commercial launch. The favorable clinical profile, indicating significant anti-tumor activity and a relatively benign safety profile, is expected to be a key factor in market penetration and revenue generation.
4. Expansion into Additional Solid Tumor Indications: Beyond ovarian cancer, rezatapopt is being developed with a tumor-agnostic approach, targeting the p53 Y220C mutation across various solid tumors. Successful clinical development and subsequent regulatory approvals for additional indications, such as breast, small-cell lung, and endometrial cancers where promising response rates have been observed, would significantly expand the addressable market and serve as a substantial driver of long-term revenue growth.

Share Issuance

• PMV Pharmaceuticals has historically financed its growth through significant equity dilution by selling shares.
• The company increased its additional paid-in capital by approximately $3.289 million from December 31, 2024, to June 30, 2025.
• PMV Pharmaceuticals relies almost entirely on shareholder equity to fund its assets, with a Debt-to-Equity ratio of 0.01 as of the latest financial reports for the 2025 fiscal year.

Inbound Investments

• BML Investment Partners disclosed a 6.3% stake in PMV Pharmaceuticals in December 2024.
• As of March 5, 2026, PMV Pharmaceuticals had 68 institutional owners and shareholders, holding a total of 37,466,853 shares, with institutional ownership strong at 70.72%.

Capital Expenditures

• Net cash used in operations, largely driven by research and development (R&D) expenses, increased to $73.6 million for the full year 2025, up from $51.3 million in 2024.
• R&D expenses were $69.9 million for the year ended December 31, 2025.
• The increase in R&D expenses was primarily due to increased contractual research organization costs for the advancement of the rezatapopt program.